Stallergenes, DBV to develop birch allergy product

Stallergenes S.A. (Euronext:GENP) and DBV Technologies (Euronext:DBV) will develop and commercialize a birch allergy product using DBV's Viaskin skin patch technology and birch pollen allergen from Stallergenes. DBV will conduct and Stallergenes will fund preclinical work. Stallergenes will then have full development and commercialization rights. DBV is eligible for up to EUR 145 million ($196.7 million) in milestones, plus royalties. Stallergenes also acquired a 2% equity stake in DBV.

Stallergenes and DBV first partnered in May to develop immunotherapies for respiratory allergies. Under that deal, the partners are signing separate agreements for selected aeroallergens to determine the terms of development and commercialization. ...